Mirae Asset Global Investments Co. Ltd. Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mirae Asset Global Investments Co. Ltd. boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,369 shares of the medical research company's stock after acquiring an additional 2,982 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Thermo Fisher Scientific were worth $28,374,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. LaFleur & Godfrey LLC increased its stake in Thermo Fisher Scientific by 9.1% in the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock worth $15,486,000 after acquiring an additional 2,488 shares during the last quarter. Brighton Jones LLC lifted its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG raised its stake in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock worth $79,677,000 after purchasing an additional 461 shares during the last quarter. Finally, SVB Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $3,545,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 0.6%

Shares of NYSE:TMO traded down $2.45 during trading on Monday, reaching $405.83. 3,919,130 shares of the stock were exchanged, compared to its average volume of 1,959,714. The stock has a fifty day moving average of $409.74 and a two-hundred day moving average of $482.94. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. The firm has a market cap of $153.20 billion, a price-to-earnings ratio of 23.80, a price-to-earnings-growth ratio of 2.17 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The business had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the business posted $5.11 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up .2% on a year-over-year basis. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.42%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analysts Set New Price Targets

Several research firms have weighed in on TMO. Royal Bank Of Canada dropped their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Scotiabank dropped their target price on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a report on Friday, April 25th. Finally, Citigroup cut their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $604.05.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president owned 23,167 shares of the company's stock, valued at $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.